Can I Take Zinc With MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Add Zinc?

MK-677 is an orally active, non-peptide agonist of the ghrelin receptor (growth hormone secretagogue receptor 1a, GHSR-1a). It stimulates pulsatile growth hormone (GH) release and raises insulin-like growth factor-1 (IGF-1) without requiring injections. Zinc is one of the most common over-the-counter supplements and overlaps with MK-677 users because zinc is required for GH receptor binding and testosterone biosynthesis.

How MK-677 Works

MK-677 mimics ghrelin at the GHSR-1a receptor in the hypothalamus and pituitary, increasing GH pulse amplitude and duration. In a key two-year randomized controlled trial (N=65 elderly adults), once-daily MK-677 25 mg increased IGF-1 by roughly 60% and GH by approximately 97% above baseline versus placebo 1. GH and IGF-1 remained elevated throughout the 24-month study period without meaningful tachyphylaxis.

Why Users Pair Zinc With MK-677

Zinc is an essential trace mineral involved in more than 300 enzymatic reactions 2. Users combining it with MK-677 typically do so because:

• Zinc is a cofactor for 5-alpha reductase and aromatase activity, affecting testosterone-to-estrogen balance.
• Animal and human data suggest zinc deficiency suppresses GH secretion and reduces IGF-1 3.
• MK-677 raises appetite (via ghrelin mimicry), and athletes using it in caloric-surplus phases often supplement zinc to offset sweat losses.

Is There a Direct Drug-Supplement Interaction Between MK-677 and Zinc?

No direct pharmacokinetic interaction has been identified. MK-677 is metabolized primarily via cytochrome P450 3A4 (CYP3A4) and is not a known substrate or inhibitor of the zinc transporter proteins (ZIP and ZnT families) that govern zinc absorption 4. Zinc absorption occurs in the small intestine via ZIP4 and is regulated independently of CYP450 pathways 5.

Pharmacokinetic Assessment

Because the two compounds travel through separate metabolic routes, co-administration does not meaningfully alter the plasma half-life or bioavailability of either agent. MK-677 reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours after an oral dose 6. Zinc absorption peaks within 1 to 2 hours of ingestion and is unaffected by CYP3A4 activity.

The absence of a pharmacokinetic clash means no mandatory dose-separation window exists. Taking both compounds with the same meal is acceptable.

Pharmacodynamic Overlap: Where Caution Is Needed

The real concern is pharmacodynamic and indirect. Both MK-677 and zinc touch the GH-IGF-1 axis, testosterone synthesis, and insulin sensitivity, so layering high doses of each may produce additive hormonal stress rather than direct chemical interference.

Zinc supports GH secretion in part by acting as a cofactor for growth hormone-releasing hormone (GHRH) signaling and IGF-1 receptor activity 3. Adding MK-677 on top of adequate zinc may amplify IGF-1 elevations beyond intended ranges, raising the theoretical risk of IGF-1-related side effects (edema, insulin resistance, paresthesias).

How Zinc Affects the GH-IGF-1 Axis

Zinc deficiency measurably suppresses both GH secretion and IGF-1 production. A clinical study in zinc-deficient adolescent boys found that zinc repletion restored IGF-1 concentrations toward normal 3. This data underpins the rationale for maintaining adequate zinc status while using any GH secretagogue.

Zinc and GH Receptor Binding

GH receptor (GHR) dimerization, the step required for downstream JAK2-STAT5 signaling, depends on zinc ions at the receptor interface. Without adequate zinc, GHR coupling efficiency drops, and circulating GH elevations produce a blunted IGF-1 response 7. From a practical standpoint, correcting frank zinc deficiency before starting MK-677 likely produces a more consistent IGF-1 response to ibutamoren.

Zinc, Testosterone, and Aromatase

Zinc inhibits aromatase activity in vitro, reducing the conversion of testosterone to estradiol 8. MK-677 may modestly raise estradiol in some users through increased GH-driven aromatase substrate availability. Adequate, not excessive, zinc may help moderate that shift without introducing the copper-depletion risk that high-dose zinc carries.

The Zinc-Copper Balance Problem at High Doses

High-dose zinc supplementation is the single most important safety issue when combining zinc with any long-term hormonal protocol. Zinc and copper compete for intestinal absorption via the metal transporter DMT1 and the mucosal metallothionein system 9. When zinc intake consistently exceeds 50 mg/day, copper absorption falls, and serum ceruloplasmin drops, eventually producing copper-deficiency anemia and neurological symptoms.

NIH Tolerable Upper Intake Level

The NIH Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for zinc at 40 mg per day for adults 2. Chronic intake above this threshold is associated with impaired copper status even without overt symptoms. A systematic review published in the American Journal of Clinical Nutrition confirmed that zinc intakes of 60 mg/day for 10 weeks significantly reduced erythrocyte copper-zinc superoxide dismutase activity, a sensitive marker of copper depletion 9.

Why Copper Matters on MK-677

Copper is a cofactor for cytochrome c oxidase, ceruloplasmin, and dopamine beta-hydroxylase. Adequate copper is needed for normal GH pulsatility because dopaminergic tone influences hypothalamic GHRH release 10. Copper deficiency could therefore blunt the very GH-axis response that MK-677 is used to amplify, creating an unintentional ceiling on efficacy.

Recommended Copper Co-Supplementation Ratio

The standard clinical ratio used to prevent zinc-induced copper depletion is approximately 10:1 to 15:1 (zinc to copper). For a user taking 25 mg elemental zinc daily, 1.5 to 2 mg copper gluconate or copper bisglycinate per day is a reasonable co-supplement 2. The NIH RDA for copper in adults is 0.9 mg/day, with a UL of 10 mg/day 2.

What the Clinical Trials Say About MK-677 Safety Profiles

No registered trial has specifically studied zinc co-administration with MK-677. However, the published MK-677 safety data provides context for how the compound behaves hormonally, which informs how zinc stacking should be approached.

GHSR Agonism and Insulin Resistance

The two-year Healthy Older Adults trial showed that MK-677 25 mg/day increased fasting blood glucose by a mean of 0.3 mmol/L (5.4 mg/dL) and fasting insulin by approximately 10 µIU/mL versus placebo 1. High-dose zinc supplementation (above 40 mg/day) has separately been linked to impaired insulin sensitivity in some observational studies 11. Stacking both in high doses may additively worsen glucose tolerance, particularly in pre-diabetic individuals.

MK-677 and Edema

Water retention is the most common MK-677 side effect, reported in roughly 30 to 40% of users in clinical trials 1. Zinc does not directly worsen edema, but high-dose zinc-induced nausea can reduce adherence to electrolyte management, indirectly affecting fluid balance.

IGF-1 Range Monitoring

The American Association of Clinical Endocrinology recommends monitoring IGF-1 when using GH-axis-active agents, targeting age-adjusted normal ranges rather than supraphysiologic levels 12. Users on MK-677 who add zinc to correct deficiency may see IGF-1 rise faster than expected. Checking IGF-1 at baseline and again 8 to 12 weeks after initiating both agents provides the data needed to adjust MK-677 dosing.

Practical Dosing and Timing Guidance

No dose-separation window is required between zinc and MK-677. The following framework represents reasonable clinical practice based on published pharmacology, not a head-to-head interaction study.

Zinc Dosing on MK-677

• Deficiency confirmed (serum zinc <70 µg/dL): 25 to 40 mg elemental zinc daily, with 1.5 to 2 mg copper, until zinc normalizes.
• Normal baseline zinc: 11 to 15 mg elemental zinc daily (close to the RDA of 11 mg for men, 8 mg for women) is adequate and carries minimal copper displacement risk 2.
• Avoid: Zinc doses above 40 mg/day without confirmed deficiency and concurrent copper monitoring.

Timing Relative to MK-677

MK-677 is typically taken once daily, often at night to align with the natural nocturnal GH pulse. Zinc taken with food reduces gastrointestinal irritation. Taking zinc with an evening meal and MK-677 at bedtime spaces them by 1 to 2 hours, which is sufficient given the absence of a pharmacokinetic interaction. Same-meal dosing is also acceptable.

Forms of Zinc

Zinc bisglycinate and zinc picolinate show superior absorption compared with zinc oxide in head-to-head comparisons 13. For users specifically concerned about gut tolerance alongside MK-677-driven appetite changes, chelated forms (bisglycinate, picolinate) cause less nausea than zinc sulfate.

Monitoring Recommendations

Anyone combining zinc supplementation with MK-677 for more than 4 weeks should consider the following monitoring schedule. These are practical clinical benchmarks, not regulatory requirements.

Baseline Labs (Before Starting)

• Serum zinc (reference: 70 to 120 µg/dL)
• Serum copper (reference: 70 to 140 µg/dL)
• Ceruloplasmin (reference: 20 to 35 mg/dL)
• Fasting glucose and fasting insulin (HOMA-IR)
• IGF-1 (age-adjusted reference range)
• Complete metabolic panel

Follow-Up Labs (8 to 12 Weeks)

• Serum zinc and copper
• IGF-1 (target: upper half of age-adjusted normal range, not supraphysiologic)
• Fasting glucose

If ceruloplasmin drops below 20 mg/dL at any point, reduce zinc dose and add or increase copper supplementation. The National Institutes of Health note that ceruloplasmin is a more sensitive early marker of copper depletion than serum copper alone 2.

Special Populations and Contraindications

Individuals With Pre-Diabetes or Insulin Resistance

Both MK-677 and high-dose zinc carry independent signals for glucose dysregulation. The GHSR-1a agonism of MK-677 raises fasting insulin; zinc above 40 mg/day may reduce insulin sensitivity 11. For anyone with a fasting glucose above 100 mg/dL or HOMA-IR above 2.5, keeping zinc at the RDA level (8 to 11 mg) and monitoring glucose every 4 weeks is the safest approach.

Adolescents and Young Adults Under 25

MK-677 is not FDA-approved for any indication. The FDA has not evaluated ibutamoren for safety in persons under 18, and open growth plates represent a theoretical concern with chronic IGF-1 elevation 14. Zinc is generally safe in adolescents at RDA doses but does not change the fundamental regulatory status of MK-677.

Prostate Health

Both elevated IGF-1 and zinc have been independently associated with prostate cell proliferation in epidemiologic studies 15. Men with a personal or family history of prostate cancer should discuss both agents with a urologist before use.

Regulatory and Legal Status of MK-677

MK-677 is not approved by the FDA as a drug or dietary supplement. It is classified as an investigational compound and appears on the World Anti-Doping Agency (WADA) prohibited list under section S2 (peptide hormones, growth factors, related substances, and mimetics) 16. Zinc, by contrast, is an established dietary supplement regulated under DSHEA (1994) and is widely available over the counter. Users should understand the legal distinction before combining the two.

Summary Table: Zinc With MK-677 at a Glance

| Parameter | Details | |---|---| | Interaction type | Pharmacodynamic (indirect), no pharmacokinetic clash | | Minimum safe zinc dose | 8 to 11 mg/day (RDA) | | Maximum recommended zinc | 40 mg/day (NIH UL) | | Copper co-supplementation threshold | Add 1.5 to 2 mg copper when zinc exceeds 25 mg/day | | Dose-separation window | Not required | | Key monitoring markers | Serum zinc, copper, ceruloplasmin, IGF-1, fasting glucose | | MK-677 regulatory status | Investigational; not FDA-approved | | Primary interaction risk | Copper depletion at high zinc doses |